Biotech | March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
The protections extend through at least 2035, with the potential for further extensions
The protections extend through at least 2035, with the potential for further extensions
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The FDA classified LifeVac as a Class II medical device
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
Subscribe To Our Newsletter & Stay Updated
